Legal Representation
Attorney
Lisa Bollinger Gehman
USPTO Deadlines
Next Deadline
1235 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2022-12-06)
Due Date
December 06, 2028
Grace Period Ends
June 06, 2029
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
36 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Dec 6, 2022 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Dec 6, 2022 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Nov 1, 2022 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | Loading... |
| Oct 31, 2022 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | Loading... |
| Oct 12, 2022 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Oct 12, 2022 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE | Loading... |
| Sep 29, 2022 | EISU | I | TEAS STATEMENT OF USE RECEIVED | Loading... |
| Sep 29, 2022 | IUAF | S | USE AMENDMENT FILED | Loading... |
| May 10, 2022 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Mar 15, 2022 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Mar 15, 2022 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Feb 23, 2022 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Feb 6, 2022 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Feb 4, 2022 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Feb 3, 2022 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Feb 2, 2022 | ERFR | I | TEAS REQUEST FOR RECONSIDERATION RECEIVED | Loading... |
| Feb 2, 2022 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Aug 18, 2021 | CNFR | R | FINAL REFUSAL WRITTEN | Loading... |
| Aug 18, 2021 | GNFR | O | FINAL REFUSAL E-MAILED | Loading... |
| Aug 18, 2021 | GNFN | O | NOTIFICATION OF FINAL REFUSAL EMAILED | Loading... |
| Jan 14, 2021 | RCSC | S | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | Loading... |
| Jun 24, 2020 | RCSC | S | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | Loading... |
| Dec 20, 2019 | CNSL | R | SUSPENSION LETTER WRITTEN | Loading... |
| Dec 20, 2019 | GNSL | S | LETTER OF SUSPENSION E-MAILED | Loading... |
| Dec 20, 2019 | GNS3 | O | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | Loading... |
| Dec 4, 2019 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Dec 3, 2019 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Dec 3, 2019 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Aug 23, 2019 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Aug 23, 2019 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Aug 23, 2019 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Aug 21, 2019 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jun 24, 2019 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Jun 18, 2019 | MDSC | E | NOTICE OF DESIGN SEARCH CODE E-MAILED | Loading... |
| Jun 15, 2019 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Jun 4, 2019 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 042
Research and development of drugs in the fields of oncology, hematology, autoimmune diseases, and rare diseases; scientific research for medical purposes in the fields of oncology, hematology, autoimmune diseases, and rare diseases; clinical research in the fields of oncology, hematology, autoimmune diseases, and rare diseases; scientific research and development of pharmaceuticals and biopharmaceuticals for the treatment of cancer, hematological diseases, autoimmune diseases, and rare diseases; providing websites featuring medical and scientific research information about pharmaceutical and biopharmaceutical drugs and their preparations; genetic testing for scientific research; genetic research in the fields of oncology, hematology, autoimmune diseases, and rare diseases; none of the foregoing in relation to or in the field of fertility
First Use Anywhere:
Apr 20, 2017
First Use in Commerce:
Apr 20, 2017
Additional Information
Design Mark
The mark consists of a series of DNA strands formed into an eight-pointed star shaped design, to the right of the design appears the word "PRELUDE" having the first letter capitalized and the word "THERAPEUTICS" in smaller capital block letters centered below "PRELUDE.".
Color Claim
Color is not claimed as a feature of the mark.
Classification
International Classes
042
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
General Disclaimer
"THERAPEUTICS"